Diadema Partners LP Buys Shares of 14,719 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Diadema Partners LP acquired a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 14,719 shares of the specialty pharmaceutical company's stock, valued at approximately $1,813,000. Jazz Pharmaceuticals accounts for approximately 0.8% of Diadema Partners LP's portfolio, making the stock its 28th largest position.

Several other large investors have also recently bought and sold shares of the business. Bessemer Group Inc. boosted its position in shares of Jazz Pharmaceuticals by 0.3% during the 4th quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company's stock worth $3,317,000 after purchasing an additional 92 shares in the last quarter. CIBC Asset Management Inc boosted its holdings in Jazz Pharmaceuticals by 5.2% during the fourth quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company's stock worth $243,000 after buying an additional 97 shares in the last quarter. Synovus Financial Corp boosted its holdings in Jazz Pharmaceuticals by 0.5% during the fourth quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company's stock worth $2,365,000 after buying an additional 100 shares in the last quarter. Quadrant Capital Group LLC grew its position in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after buying an additional 101 shares during the period. Finally, UMB Bank n.a. increased its holdings in Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock valued at $38,000 after buying an additional 129 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the transaction, the chief executive officer now owns 439,744 shares in the company, valued at $53,785,088.64. This represents a 0.34 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Patricia Carr sold 1,140 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the completion of the sale, the chief accounting officer now directly owns 7,012 shares of the company's stock, valued at $966,323.72. This trade represents a 13.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,736 shares of company stock valued at $4,023,305 over the last quarter. Company insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Up 1.7 %

Jazz Pharmaceuticals stock traded up $1.82 during trading on Friday, reaching $110.80. 896,340 shares of the company's stock were exchanged, compared to its average volume of 797,223. Jazz Pharmaceuticals plc has a 52-week low of $95.49 and a 52-week high of $148.06. The firm has a market cap of $6.73 billion, a price-to-earnings ratio of 15.61, a PEG ratio of 1.04 and a beta of 0.42. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company's 50-day moving average is $125.13 and its two-hundred day moving average is $122.18.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of research reports. Morgan Stanley restated an "overweight" rating and issued a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. JPMorgan Chase & Co. upped their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Needham & Company LLC reiterated a "buy" rating and issued a $210.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, April 10th. Barclays reiterated an "overweight" rating and issued a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Finally, Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.